(Boursier.com) — The 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will be held from June 22 to 26, 2024 in Bangkok, Thailand, will be an opportunity to Sanofi to present new data on its hematology product portfolio.
Among the notable communications devoted to ALTUVIIIO [facteur antihémophilique (recombinant), protéine de fusion Fc-VWF-XTEN] Includes interim data from a long-term phase III study relating to its effectiveness and safety in adults and children with severe hemophilia A. Regarding fitusiran, the abstracts presented will focus on its perioperative administration, as well as its long-term safety within the framework of the ATLAS phase III clinical development program, in adults and adolescents with hemophilia. A or B, with or without inhibitors.
Dietmar Berger, Chief Medical Officer, Global Head, Development, comments: “Our presence at this year’s congress demonstrates how committed we are to bringing innovative solutions, which are the first and best in their pharmacotherapeutic class, to the community of hemophilia A disease that lasts a lifetime, hemophilia has serious consequences on the lives of people who suffer from it, whether it is the risk of bleeding, joint effusions or other risks. bleeding during surgery These data demonstrate the importance of having new treatment options, such as ALTUVIIIO and fitusiran, that are effective in a variety of settings and can be administered across the lifespan. regulatory bodies to continue to make new therapeutic solutions available to hemophilia patients.”
©2024 Boursier.com